Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

mplied discussions regarding the potential development and marketing of potential future respiratory products, regarding potential future launches of indacaterol, or regarding potential future revenues from indacaterol. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Novartis will successfully develop or bring to market any additional respiratory products.  Nor can there be any guarantee that indacaterol will be launched in any particular countries, or at any particular time.  Neither can there be any guarantee that indacaterol will achieve any particular levels of revenue in the future. In particular, management's expectations regarding indacaterol could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including unexpected reimbursement difficulties or delays; competition in general; government, industry and general public pricing pressures; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Inc. (Nasdaq: BMRN ) today announced that Joshua ... will present a company update at the Deutsche Bank 2010 ... 9:00 a.m. ET.   Interested parties may access ... investor section of the BioMarin website, www.BMRN.com .  A ...
... Dec. 6, 2010 SI-BONE, Inc. (San Jose, California), a ... minimally invasive surgical (MIS) device to treat the sacroiliac (SI) ... Institute, has joined its Medical Advisory Board (MAB). Dr. Rashbaum ... and Nick Shamie, along with SI-BONE founder, Mark Reiley, on ...
Cached Medicine Technology:BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 3SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 4
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... least $50 billion in fuel costs now ... The current GHG standards are ... taken it upon themselves to install new ... , 1.    Idle reduction technologies , 2.    Efficient driveline ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... 11, 2014 Alliance for Cancer ... non-profit dedicated exclusively to cell and gene therapies ... has joined the organization as Senior Development Officer. ... deep experience securing gifts and addressing influential donors. ... Giving Director for NewYork Presbyterian Hospital/Columbia University Medical ...
(Date:7/11/2014)... Biostimulants are widely applied in turf and ... These also help turf and ornamentals in absorption of ... ornamentals, and flowers appear healthy and strong as a ... from the last few years. The most dominating region ... with around 40% share in 2013, and is estimated ...
(Date:7/11/2014)... Miriam Hospital have found that people with mobility ... of smoking than those without mobility impairments. Additionally, ... attempt quitting than those without mobility impairments, and ... this population. The study and its findings are ... American Journal of Public Health . ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Miriam Hospital study examines smoking prevalence 2
... , RICHMOND, Calif., Aug. 18 Transcept ... to reduce operating expenses by eliminating certain staff positions following ... Products to commercialize Intermezzo ((R) )(zolpidem tartrate sublingual tablet) ... Glenn A. Oclassen, President and Chief Executive Officer commented, ...
... SAN DIEGO, Aug. 18 Aethlon Medical, ... present at today,s 14th Annual Southern California Investor Conference ... California. The conference is hosted by California Equity Research ... world-recognized life science, technology, media, and real estate/financial organizations. ...
... ... today announced that the hemostatic HemCon Patch™ and HemCon® Bandage ... with Premier Purchasing Partners L.P., the group purchasing unit of Premier ... 2011. The agreement makes HemCon dressings available at pre-negotiated terms to ...
... , INDIANAPOLIS, Aug. 18 "If commercial flying ... fire, there would be a public revolt," said Rob Schnepp, CPTC ... Fire Department in California. "The numbers aren,t going down, and this ... NFPA study reveals 87-percent of people who died in fires had ...
... ... States Health Alliance Admitted to Talent Management Organization , ... Atkins, VA (PRWEB) August 18, 2009 -- The ... world-class companies, has two new members, Qwest, headquartered in Denver, Colorado, and Mountain States ...
... , ... Group (ISG), a nationwide network of identification and card issuance sales and service experts, ... the Medical Group Management Association (MGMA). , ... Kansas City, MO (PRWEB) August 18, 2009 -- Identification Systems ...
Cached Medicine News:Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 2Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 3Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 4Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 5Health News:Aethlon Medical to Present at Today's Southern California Investor Conference 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 3Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 2Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 2Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 4Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 2Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 3
Alpha prime immunoassay system features unsurpassed quality of results, full automation of EIA tests for microplate applications, complete walk-away, up to 18 different assays per run, photometric an...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
Medicine Products: